Home Business Life Sciences and Bio Pharma Samsung Invests in Phrontline,...

Samsung Invests in Phrontline, Improving Next-Gen Cancer Drug Development

Life Sciences and Bio Pharma

Business Honor Samsung backs Phrontline cancer R&D

Business Honor
25 November, 2025

Samsung invested in Phrontline to advance cancer-targeting ADC drugs, growing its biopharma presence and future precision oncology capabilities.

Samsung has invested in a Chinese biotechnology startup, Phrontline Biopharma that is developing next-generation antibody-drug conjugates (ADCs). The investment was made with the Samsung Life Science Fund, that is managed by Samsung C&T, Samsung Biologics, and Samsung Bioepis. As part of Samsung's aim to increase its presence in the worldwide biopharmaceutical sector.

The amount of the investment was not disclosed, but Samsung stated that the funds will help to improve research collaboration with Phrontline, which is developing bispecific and double-payload ADC platforms for cancer treatment. Phrontline is currently conducting a worldwide clinical study for its bispecific antibody-based ADC candidate, with plans to begin trials for its bispecific, dual-payload program in the first quarter of next year.

The latest development improves on the partnership between Samsung Bioepis and Phrontline that began last year. Under this agreement, the businesses agreed to work together on the development, production, and marketing of ADC medication concepts. Samsung Bioepis gained co-development rights for two Phrontline programs, as well as a sole right to use one of the business's payload technologies on its own drugs.

"By investing in Phrontline after partnering with them, we will gain major technological influence in the worldwide ADC market," said Seo Min-jeong, vice president of Samsung Bioepis. Min-jeong stated that the business will continue to grow its technological capabilities through partnerships and investments. Since its beginnings in 2021, the Samsung Life Science Fund has invested in a number of modern biopharmaceutical areas, including gene therapy, blood protein analysis, AI-powered protein drug discovery, and gene-editing technologies.

With this latest investment, Samsung moves deeper into cancer treatment precision. Experts expect that as ADC technologies advance, the next generation will see more flexible, highly specific cancer treatments, therapies that can adapt faster and act smarter, slowly changing how future cancer care is created and provided.